1171476-07-5 Usage
Uses
Used in Pharmaceutical Industry:
2-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinehydrochloride is used as a central nervous system stimulant for its ability to enhance dopamine receptor activity, which may be beneficial in the treatment of neurological disorders such as Parkinson's disease. Its agonistic effect on dopamine receptors could potentially alleviate symptoms associated with dopamine deficiency.
Used in Research and Development:
In the field of medical research, 2-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinehydrochloride serves as a valuable compound for studying the mechanisms of dopamine receptor modulation. It is utilized in preclinical studies to explore its therapeutic potential for a range of psychiatric and neurological conditions, with the aim of advancing understanding and developing new treatment options.
Used in Drug Discovery:
2-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinehydrochloride is employed in drug discovery processes as a lead compound for the development of new pharmaceuticals targeting the dopamine system. Its structural and functional characteristics make it a promising candidate for the design of novel therapeutic agents that could address unmet medical needs in the treatment of various neurological and psychiatric disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 1171476-07-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,7,1,4,7 and 6 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1171476-07:
(9*1)+(8*1)+(7*7)+(6*1)+(5*4)+(4*7)+(3*6)+(2*0)+(1*7)=145
145 % 10 = 5
So 1171476-07-5 is a valid CAS Registry Number.
1171476-07-5Relevant academic research and scientific papers
ANNULATED GLYCOSIDASE INHIBITORS
-
Page/Page column 94, (2019/03/12)
Compounds of formula (I) wherein A, R, W1, W2, W3, W4, W5, W6, L, Q, Rx and u have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
NOVEL (HETEROCYCLE/CONDENSED PIPERIDINE)-(PIPERAZINYL)-1-ALKANONE OR (HETEROCYCLE/CONDENSED PYRROLIDINE)-(PIPERAZINYL)-1-ALKANONE DERIVATIVES AND USE THEREOF AS p75 INHIBITORS
-
, (2012/10/08)
The disclosure relates to (heterocycle-fused piperidine)-(piperazinyl)-1-alkanone derivatives and (heterocycle-fused pyrrolidine)-(piperazinyI)-1-alkanone derivatives of formula (I): wherein A, W, R2 and n are as defined in the disclosure, to the method o
